In April 2020, Pemigatinib (PEMAZYRE) received approval by FDA for the treatment of adults with previously treated, unresectable locally advanced or metastatic bile duct cancer (cholangiocarcinoma) with a fibroblast growth factor receptor 2 (FGFR2) fusion. Pemigatinib is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with antineoplastic activity. It binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. This drug contains 1H-pyrrolo[2,3-b]pyridine moiety in its backbone. We have made a set of Building Blocks, which contain such part – the perfect start for your research!